---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-092566"
form_type: "8-K"
ticker: "RGNX"
cik: "0001590877"
company_name: "REGENXBIO Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:39:52.616526+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# REGENXBIO Q4 net loss $67.1M; FDA holds on RGX-121/111; RGX-202 data expected Q2 2026

## Summary
- Q4 2025 net loss $67.1M ($1.30/sh) vs $51.2M loss ($1.01/sh) in Q4 2024; FY net loss $193.9M ($3.76/sh).
- Revenues for full year 2025 $170.4M (up from $83.3M in 2024) driven by Nippon Shinyaku partnership and royalty increases.
- Cash and marketable securities $240.9M at Dec 31, 2025; expects operations funded into early 2027.
- FDA placed clinical holds on RGX-121 and RGX-111; issued Complete Response Letter for RGX-121 BLA in Feb 2026.
- RGX-202 for Duchenne: topline pivotal data expected early Q2 2026; pre-BLA meeting mid-2026. Sura-vec wet AMD data expected Q4 2026.

## SEC filing metadata
- accession: 0001193125-26-092566
- form_type: 8-K
- ticker: RGNX
- cik: 0001590877
- company_name: REGENXBIO Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590877/000119312526092566/0001193125-26-092566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590877/000119312526092566/rgnx-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-092566
- JSON: https://secwatch.observer/filing/0001193125-26-092566.json
- Plain text: https://secwatch.observer/filing/0001193125-26-092566.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.